SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Clements PJ, Lachenbruch PA, Ng SC, Simmons M, Sterz M, Furst DE. Skin score: a semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis Rheum 1990; 33: 125663.
  • 2
    Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 12815.
  • 3
    Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 163047.
  • 4
    Kissin EY, Schiller AM, Gelbard RB, Anderson JJ, Falanga V, Simms RW, et al. Durometry for the assessment of skin disease in systemic sclerosis. Arthritis Rheum 2006; 55: 6039.
  • 5
    Kissin EY, Merkel PA, Lafyatis R. Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. Arthritis Rheum 2006; 54: 365560.
  • 6
    Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al, on behalf of the CAT-192 Study Group and the Scleroderma Clinical Trials Consortium. Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 32333.
  • 7
    Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic schlerosis. Arthritis Care Res 1991; 4: 2731.
  • 8
    Steen VD, Medsger TA Jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum 1997; 40: 198491.
  • 9
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al, for the Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 241020.
  • 10
    Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. New York: Wiley; 2004.
  • 11
    Rawlings JO. Applied regression analysis: a research tool. Belmont (CA): Wadsworth; 1988.
  • 12
    Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27(3 Suppl ): S17889.
  • 13
    Hawley DJ, Wolfe F. Sensitivity to change of the Health Assessment Questionnaire (HAQ) and other clinical and health status measures in rheumatoid arthritis: results of short-term clinical trials and observational studies versus long-term observational studies. Arthritis Care Res 1992; 5: 1306.
  • 14
    Liang MH, Larson MG, Cullen KE, Schwartz JA. Comparative measurement efficiency and sensitivity of five health status instruments for arthritis research. Arthritis Rheum 1985; 28: 5427.
  • 15
    Falanga V, Bucalo B. Use of a durometer to assess skin hardness. J Am Acad Dermatol 1993; 29: 4751.
  • 16
    Aghassi D, Monoson T, Braverman I. Reproducible measurements to quantify cutaneous involvement in scleroderma. Arch Dermatol 1995; 131: 11606.